Estrogen deficiency promotes bone loss and skeletal muscle dysfunction. Peroxisome proliferatoractivated receptors (PPARs) have 3 subtypes (␣, ␦, and ␥). PPAR␥ agonists induce bone loss, whereas PPAR␣ agonists increase bone mass. Although PPAR␦ agonists are known to influence skeletal muscle metabolism, the skeletal effects are unsettled. This study investigated the musculoskeletal effects of the PPAR␦ agonist GW501516 in ovariectomized (OVX) rats. Female Sprague Dawley rats, 12 weeks of age, were allocated to a sham-operated group and 3 OVX groups; high-dose GW501516 (OVX-GW5), low-dose GW501516 (OVX-GW1), and a control group (OVX-CTR), respectively (n ϭ 12 per group). Animals received GW501516 or vehicle (methylcellulose) daily for 4 months by gavage. Bone mineral density (BMD) was assessed by dual x-ray absorptiometry at the femur, spine, and whole body. Bone microarchitecture at the proximal tibia was assessed by microcomputed tomography, and dynamic histomorphometry was performed. Quadriceps muscle morphology and the relative expression of mitochondrial proteins were analyzed. Bone metabolism markers and metabolic markers were measured in plasma. After 4 months, the OVX-GW5 group displayed lower femoral BMD than OVX-CTR. Trabecular separation was higher in the GW-treated groups, compared with OVX-CTR. The OVX-GW5 group also exhibited lower cortical area fraction and a higher structure model index than OVX-CTR. These effects coincided with impaired bone formation in both GW groups. The OVX-GW5 group displayed elevated triglyceride levels and reduced adiponectin levels, whereas no effects on muscle morphology or mitochondrial gene expression appeared. In summary, the PPAR␦ agonist GW501516 negatively affected bone properties in OVX rats, whereas no effects were detected in skeletal muscle. (Endocrinology 155: 2178 -2189, 2014) E strogen deficiency after menopause induces bone loss and skeletal muscle dysfunction and increases the risk of osteoporosis and sarcopenia (1, 2). Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors acting as transcription factors with a ubiquitous expression, including in bone and skeletal muscle cells. There are 3 subtypes; ␣, ␦, and ␥, which are all known as important regulators of energy metabolism and homeostasis. PPAR agonists are used in the treatment of type 2 diabetes mellitus and hyperlipidemia, and PPARs have also been suggested as potential targets in the treatment of osteoporosis and sarcopenia (3-6). Abbreviations: ANGPTL4, angiopoietin-like 4; BMC, bone mineral content; BMD, bone mineral density; BrdU, 5-bromo-2Ј-deoxyuridine; CPT1, carnitine palmitoyl transferase 1; CT, microcomputed tomography; CTX, carboxyl-terminal collagen cross-links; DXA, dual x-ray absorptiometry; FCS, fetal calf serum; LPL, lipoprotein lipase; OPG, osteoprotegerin; OVX, ovariectomized; PDK4, pyruvate dehydrogenase kinase 4; PPAR, peroxisome proliferator-activated receptor; RANKL, receptor activator of nuclear factor-B ligand; SMI, structure model index; UCP3, uncoupling protein 3.
PPAR␥ agonists have been shown to cause bone loss in vivo (7) (8) (9) (10) , and to promote the differentiation of mesenchymal stem cells into adipocytes at the expense of osteoblastogenesis in vitro (9, (11) (12) (13) . Still et al (14) found that the dual PPAR␣/␦ agonists linoleic acid and bezafibrate induced differentiation of osteoblasts in vitro and increased metaphyseal bone mineral density (BMD) in male rats. Previously, our group demonstrated an increase in BMD by a more specific PPAR␣ agonist, fenofibrate, in both intact and ovariectomized (OVX) female rats (9, 10) . This effect was mainly attributed to enhanced proliferation and differentiation of mesenchymal stem cells into osteoblasts (9, 10) . These findings suggest a positive impact of PPAR␣ activation on bone in rats. One recent study demonstrated that the PPAR␦-specific agonist GW501516 improved skeletal properties and bone metabolism in OVX mice (15) . The skeletal effects of PPAR␦ activation in rats, however, have not yet been explored.
We have previously reported that PPAR␣ stimulation increases muscle mass in intact and OVX rats (9, 10) . However, the role of PPAR␦ agonism in regulating skeletal muscle mass, and the possible development of sarcopenia, is still unclear. The metabolic effects of PPAR␦ activators in skeletal muscle have gained more attention than its potential effects on bone, because they ameliorate lipid metabolism, insulin sensitivity, and energy expenditure in vitro (16, 17) . Furthermore, the PPAR␦ agonist GW501516 has been shown to increase the relative expression of genes involved in fatty acid mobilization and oxidation in skeletal muscle of sedentary and trained mice, resulting in reduced lipid levels in these animals (4, 18) . These effects could, however, not be demonstrated when administering PPAR␦ agonists to rats, suggesting a species-specific effect (19, 20) . Estrogen deficiency leads to reduction in the gene expression of PPAR␦ and metabolic proteins, such as pyruvate dehydrogenase kinase 4 (PDK4), mitochondrial uncoupling protein 3 (UCP3), and carnitine palmitoyl transferase 1 (CPT1) in skeletal muscle, and decreases the amount of oxidative type I muscle fibers in mice (21) . Whether administration of PPAR␦ agonists can improve the gene expression of mitochondrial proteins and enhance lipid metabolism during estrogen deficiency has not been reported.
In the present study, we therefore investigated the longterm effects of the PPAR␦ agonist GW501516 on bone and skeletal muscle in OVX rats. We also examined the effects of this substance on proliferation and differentiation of premature osteoblasts and osteoclasts in vitro.
Materials and Methods

Animals
This study was approved by the Animal Welfare Committee at the Norwegian University of Science and Technology in Trondheim, Norway. Forty-eight female Sprague Dawley rats (12 weeks of age, 250 Ϯ 41 g) were housed in wire-top cages with aspen woodchip bedding (B&K Universal Ltd). The room temperature was 24°C Ϯ 1°C with a relative humidity of 40% to 50% and a 12-hour light, 12-hour dark cycle. Rat and mouse diet (B&K Universal Ltd), along with tap water were provided ad libitum. After 5 days of acclimatization, the animals were randomly divided into 4 groups, 12 animals in each. One group was sham-operated, whereas the other 3 groups underwent OVX to induce bone loss (22) . Two of the OVX groups were given GW501516 (Chiron AS) at 1 mg/kg/d (OVX-GW1) and 5 mg/ kg/d (OVX-GW5), respectively, using methylcellulose as vehicle. The chosen doses were based on the results from previous studies (18, 23) . Administration of test substances started 1 week after surgery and lasted for 4 months. The sham group and the OVX control group (OVX-CTR) were given vehicle only. Substances were administered by daily intragastric gavage. The day before euthanization, animals were fasted, with free access to water.
OVX was performed as previously described by Kharode et al (22) . The sham group underwent laparotomy without removal of the ovaries. Animals were anesthetized with isoflurane by inhalation (1% isoflurane mixed with 30% O 2 /70% N 2 O) during surgery and dual x-ray absorptiometry (DXA). Buprenorphine (Temgesic) analgesics were administered immediately after surgery. Before euthanization, blood samples were collected by cardiac puncture. Both hind limbs were dissected; femurs and the right tibias were stored at Ϫ80°C, whereas the left tibias were stored in ethanol for later investigations. Samples from the quadriceps muscle and abdominal fat tissue were also obtained and stored at Ϫ80°C until further analyses. The hind limbs from 8 intact female Sprague Dawley rats, 7 to 20 weeks of age, were also used for isolation of bone marrow cells for osteoblast and osteoclast differentiation studies.
Dual x-ray absorptiometry
Body weight, fat mass, and lean mass, along with bone mineral content (BMC) and BMD at the whole body, femur, and lumbar spine (L2-L4), were measured by DXA in anesthetized animals, using a Hologic QDR 4500A and small animal software. The coefficient of variation was 2.4% for body weight, 2.2% for fat mass, 0.28% for lean mass, 0.54% for whole-body BMC, 3.0% for femur BMC, 0.60% for whole-body BMD, and 0.71% for femur BMD. Measurements were performed at baseline and 3 and 4 months at all sites, except for the spine, which was measured at 3 and 4 months only.
Microcomputed tomography
Scanning was performed with desktop 1172 microcomputed tomography (CT) imaging system (Skyscan) at 11-m voxel resolution using a source voltage of 50 kV and a current of 200 A with a 0.5-mm aluminum filter to optimize contrast. Samples were rotated around their long axes with a rotation step of 0.4°. Raw images were then reconstructed with standard SkyScan reconstruction software (NRecon) to 3-dimensional cross-sectional image data sets using a 3-dimensional cone beam algorithm. For the reconstruction, beam hardening was set to 40%, smoothing to 1, and ring artifact reduction to 12. Analyses of reconstructed images were performed applying the standard SkyScan software (CTan).
Trabecular bone was analyzed in the proximal metaphysis region starting just distal to the metaphysis and continued distally for 300 slices. Cortical bone was analyzed by a region of 400 slices, starting 9 mm distal to the metaphysis. Cortical and trabecular bone were separated using an in-house developed software. Cortical volume, cortical area fraction, bone volume fraction, trabecular number, trabecular thickness, trabecular separation, and structure model index (SMI) were determined according to guidelines (24) . SMI indicates whether the trabeculae are more rod-like (SMI ϭ 3) or plate-like (SMI ϭ 0), and values between 0 and 3 represent the volume ratio of rods and plates, analyzed as previously described (25) .
Bone histomorphometry
Calcein injections for histomorphometric analyses were given 7 days and 1 day before animals were before being killed. Tibias from each animal were fixed in 70% ethanol. The bones were dehydrated in graded alcohols and embedded in methylmethacrylate at Ϫ20°C. Coronal unstained sections (7 m) were prepared and subjected to histomorphometric analyses of dynamic parameters using image analysis software (ImageJ, http://rsb. info.nih.gov/nih-image) as previously described (26) . The area examined extended from 1 to 4 mm below the growth plate. The analysis focused on 2 indices pertaining to bone formation: Interlabel width, a measure of osteoblast activity and mineralizing surface (MS/BS), a measure of tissue level bone turnover. Interlabel width was calculated by measuring area and circumference of double labels. Mineralizing surface was calculated as the fractional extent of double labels per unit trabecular surface area.
Histological and morphological analyses of muscle
A lateral part of the right quadriceps was snap-frozen in liquid N 2 or formalin-fixed. The 4-m formalin-fixed paraffin-embedded sections were stained with hematoxylin-eosin and elastin von Gieson (Sigma-Aldrich HT25A) for structural morphology.
Myofibers were stained for fast-and slow-type myosin heavy chains, respectively (NCL-MHCf and NCL-MHCs; Novocastra, Leica Microsystems). For immunohistochemical analyses, 8-m serial cryosections were used. Before staining, sections were incubated 60 minutes in 5% BSA in PBS, and endogenous peroxidase was then blocked with 0.3% H 2 O 2 . Primary antibodies were diluted 1:100 in 1% BSA in PBS, and sections were incubated for 45 minutes at room temperature. Positive staining was demonstrated using the EnVision Flex system (K800; Dako) and enhanced with 3% CuSO 4 for 5 minutes. Immunohistochemical staining applied a semiautomatic staining system and reagents (Autostainer Plus; Dako) according to the manufacturer's protocol.
The number of myofibers was counted per square millimeter on hematoxylin-eosin-stained sections, using a 100-m optical grid and a 10x/0.30 lens (Nikon Eclipse E3400, Nikon, Japan). Myofiber area was calculated on 100 randomly selected fibers. Estimation of fibrovascular content is previous described (Molon-Noblot, Toxicol Pathol 2005). All analyses used the enclosed software (NIS-Elements BR, Nikon, Japan).
Immunoassays
Triglycerides and glucose in plasma were determined using standard procedures (Cobas Trig/GB; Roche Diagnostics). Plasma osteocalcin was analyzed by a Rat-MID osteocalcin ELISA kit (Nordic Bioscience Diagnostics A/S). The detection limit was 50 ng/mL, and intra-and interassay variations were 5.0% and 5.5%. The bone resorption marker carboxyl-terminal collagen cross-links (CTX) in plasma was analyzed by a RatLaps ELISA kit (Nordic Bioscience Diagnostics A/S, Herlev, Denmark). The detection limit was 3.0 ng/mL, and intra-and interassay variations were 5.6% and 11%, respectively. Osteoprotegerin (OPG) and receptor activator of nuclear factor-B ligand (RANKL) in plasma and cell media were measured by Quantikine ELISA kits (R&D Systems). Detection limits were 4.5 and 5.0 pg/mL, intra-assay variations were 5.9% and 4.3%, and interassay variations were 7.2% and 6.9%, respectively. Insulin in plasma was analyzed by a rat insulin ELISA kit (Millipore). The detection limit was 0.2 ng/mL, and intra-and interassay variations were 1.9% and 7.6%, respectively. Plasma adiponectin levels were determined by a rat adiponectin ELISA kit (Millipore). The detection limit was 0.155 ng/mL, and intra-and interassay variations were 1.3% and 7.0%, respectively. Lowdensity lipoprotein cholesterol was measured by a reagent kit (N-Geneous LDL cholesterol reagent; Genzyme Diagnostics). Intra-and interassay variations were 1.7% and 1.5%, respectively. All analyses were performed according to the manufacturers' protocols.
Cells and reagents
MC3T3-E1 cells (mouse preosteoblasts) and RAW 264.7 cells (mouse preosteoclasts) were maintained in ␣-MEM (Invitrogen) and DMEM (Invitrogen), respectively, containing 1.5 g/L sodium pyruvate (Gibco BRL, Life Technologies Ltd), 4mM Lglutamine (Gibco), 0.1 mg/mL fungizone (Gibco), and 10 U/mL penicillin/streptomycin (Gibco) and supplemented with 10% fetal calf serum (FCS) (EuroClone). Rat L6 myoblast cells (CRL-1458; American Type Culture Collection) were maintained in DMEM supplemented with 10% FCS.
Osteoblast differentiation
Bone marrow cells were collected from femurs and tibias from 8 intact female Sprague Dawley rats and isolated as previously described (9) . Mineralizing fibroblast-colony-forming unit culture assays were performed essentially as described by Scutt et al (27) . Cells were seeded in DMEM/10% FCS (EuroClone) with 10nM dexamethasone (Sigma-Aldrich), 50 g/mL ascorbic acid (Sigma-Aldrich), and 2.0mM ␤-glycerophosphate (Sigma-Aldrich) in 6-well-plates (1.0 ϫ 10 6 cells per well). Experiments were performed in 2 or 3 biological replicates (1 for each animal), with 3 parallel wells for each concentration of GW501516 (1nM-1M), pioglitazone (10M), or control medium (differentiation medium). The media were changed after 5 days and thereafter every third day for 21 days. Medium samples were collected during differentiation for analyses of OPG and RANKL release. Alkaline phosphatase-, collagen-, and calcium-stained colonies were determined sequentially as previously described (9) and counted using the software ImageQuant TL version 7.0 (GE Healthcare Life Sciences).
Osteoclast differentiation
Bone marrow cells were collected from femurs and tibias from 3 intact female Sprague Dawley rats, as described in the osteoblast differentiation procedure. Cells were seeded in 6-well plates (1.0 ϫ 10 6 cells per well), using ␣-MEM/10% FCS and 100 ng/mL RANKL (R&D Systems) as differentiation medium. After 5 hours, the medium containing unattached cells was transferred into new 6-well plates, and differentiation medium with or without GW501516 (1nM and 0.1M) was added. The experiment was performed in 3 biological replicates, using 3 parallels for each condition. RAW 264.7 cells were cultured in 96-well plates (5000 cells per well) for 24 hours before adding differentiation media containing DMEM/10% FCS growth medium with 100 ng/mL RANKL. Experiments were performed in 2 biological replicates. GW501516 (0.1nM-10M) was added in 5 parallels, and cells were cultured for 7 days before staining for tartrateresistant acid phosphatase activity, using naphthol AS-BI phosphate and Fast Garnet in the presence of sodium tartrate, as described by the manufacturer (Sigma-Aldrich). The number of tartrate-resistant acid phosphatase-positive, multinuclear (3 or more nuclei) cells was counted.
Proliferation assays
Proliferation was studied using a kit from Roche Molecular Biochemicals. Briefly, MC3T3-E1 cells and RAW 264.7 cells were seeded in 96-well plates (4 ϫ 10 3 cells per well) and cultured for 24 hours. Cells were washed once with 200 L serum-free medium before addition of new medium with or without GW501516. After 4 hours, 5-bromo-2Ј-deoxyuridine (BrdU)-labeling solution was added, and the cells were cultured for an additional 18 hours before incorporation of BrdU was measured as described by the manufacturer. After removing the labeling medium, cells were fixed by adding 150 L FixDenat (30 minutes, room temperature). FixDenat-solution was removed, and thereafter 100 L of peroxidase-conjugated anti-BrdU antibody solution was added per well, followed by incubation (90 minutes at room temperature). The wells were washed 3 times with 200 L washing solution before 100 L of substrate luminol/4-idophenol was added. After 3 minutes, chemiluminescence was 
Gene expression studies in rat L6 myoblasts
Rat L6 myoblasts (CRL-1458; American Type Culture Collection) were seeded in 6-well plates, containing 2 mL of growth medium. All experiments were conducted using cells from passage 4, after initial culture from the source. At 70% to 80% confluence, differentiation was initiated by adding DMEM with 2% FCS with or without test substances. The cells were exposed to the PPAR␦ agonists GW501516 (1nM and 100nM) and L165,041 (10M; R&D Systems) and the PPAR␥ agonist pioglitazone (10M; R&D Systems) and compared with controls (differentiation medium only) in 3 replicates. Concentrations were chosen according to previous studies (18, 28) . Cells were lysed for RNA extraction after 7 days of exposure. The PPAR␦ target genes chosen for gene expression analyses (UCP3, CPT1, PDK4, lipoprotein lipase [LPL], and angiopoietin-like 4 [ANGPTL4]) were based on previous publications (18, 20, 29) .
mRNA isolation and cDNA synthesis
Muscle tissue (ϳ30 mg) from the quadriceps was randomly taken from 8 animals in each group and lysed in RIPA buffer (Sigma-Aldrich) using an electric knife-homogenizer. Total RNA was isolated using the RNeasy fibrous tissue mini kit (QIAGEN). Rat L6 myoblasts from the in vitro experiments were lysed in RTL buffer (QIAGEN) using a syringe and needle. Total RNA was isolated using the RNeasy Plus mini kit (QIAGEN). The amount of total RNA in each sample was measured using a NanoDrop spectrophotometer, and equal amounts of total RNA from each sample were applied directly to obtain first-strand cDNA using the iScript cDNA synthesis kit with oligodeoxythymidine (Bio-Rad).
Real-time PCR quantification
The real-time PCR analyses were carried out on a StepOne Real-Time PCR system (Applied Biosystems) according to the protocol from SABiosciences. SYBR Green dye was used for detection, and melting point analysis was performed. Table 1 shows the primer sequences, the expected sizes of the PCR products, and GenBank accession numbers used for design of the primer pairs. Intron-spanning primers were designed using the primer BLAST designing tool (NCBI). Data were calculated using the relative standard curve method, with GAPDH as the housekeeping gene.
Statistics
Data are presented as mean Ϯ SD. Data were tested for normal distribution with Shapiro-Wilk normality test. Normally distributed data were tested using one-way ANOVA and Bonferroni's posttest. Kruskal-Wallis with Dunn's posttest or MannWhitney U test was used for data that were not normally distributed. Between-groups comparison across time points (ie, DXA measurements) were performed with linear mixed models, using Bonferroni's correction, random intercept, and independent error terms within each animal. Fat and lean mass are presented as a percentage of body weight, whereas whole-body and femoral BMC and BMD data are presented as percent change from baseline. Elsewhere, data are presented as absolute values. P values Ͻ .05 were regarded as statistically significant. All statistical analyses were made using the software programs SPSS (version 19.0) and GraphPad Prism (version 5.0).
Results
Body composition and general observations
Throughout the study period, 7 animals died, 3 in the sham group, 2 in the OVX-GW1 group, and 2 in the OVX-GW5 group. No difference in the animals' wellbeing was observed between the groups throughout the study. Body weight and fat and lean mass did not differ between the groups at baseline. Body weight increased more in the OVX-CTR group compared with sham (P ϭ .04) throughout the intervention, whereas OVX-GW1 and OVX-GW5 did not differ from the other groups. After 4 months, body weight was 358 Ϯ 35 g in the OVX-CTR group vs 321 Ϯ 19 g in the sham group ( Figure 1A) . The gain in fat mass was greater in the OVX-CTR and OVX-GW1 groups than in the sham group (P Ͻ .003), whereas OVX-GW5 did not differ from any of the groups. At the end of the study, body fat was 21% Ϯ 7% and 20% Ϯ 3% in OVX-CTR and OVX-GW1 vs 11% Ϯ 3% in the sham group ( Figure 1B) . A decline in lean mass was observed in the OVX- CTR group relative to the sham group (P Ͻ .01). After the intervention, lean mass constituted 79% Ϯ 7% of total body weight in the OVX-CTR group vs 89% Ϯ 3% in the sham group ( Figure 1C ). No differences in lean mass occurred in the GW groups.
BMC and BMD of the whole body, femur, and spine
Initially, there were no differences between the groups in BMC or BMD of the whole body and femur. Wholebody and femoral BMC/BMD increased in all groups from baseline. The gain in whole-body BMC was higher in the OVX-CTR group compared with OVX-GW5, 37% Ϯ 6% vs 31% Ϯ 8% (P ϭ .031, Figure 2A ). Whole-body BMD increased more in the sham group relative to all OVX groups (P Ͻ .01, Figure 2B ). Femoral BMC also increased more in the sham group than in the OVX groups (P Ͻ .01). Furthermore, the gain in femoral BMC was greater in both the OVX-CTR (30% Ϯ 10%) and the OVX-GW1 groups (26% Ϯ 12%) than in OVX-GW5 (14% Ϯ 13%, P Ͻ .05, Figure 2C ). Femoral BMD increased more in the sham group compared with OVX-GW1 and OVX-GW5 (P Ͻ .01) and OVX-CTR (P ϭ .088, Figure 2D ), although not significantly in the latter. The OVX-CTR (13% Ϯ 6%) group also developed higher femoral BMD relative to OVX-GW5 (4% Ϯ 6%, P ϭ .018, Figure 2D ). After 3 and 4 months, lumbar spine BMD was significantly higher in the sham group compared with all OVX groups, whereas no difference between the OVX groups was observed (Supplemental Table 1 ).
Bone architecture parameters in tibia
In general, trabecular bone parameters at the proximal tibia differed between the sham and OVX groups. As expected, trabecular bone volume fraction and trabecular number were higher in the sham group compared with the OVX groups (P Ͻ .001, Table 2 ). However, trabecular thickness was higher in all OVX groups compared with the sham group (P Ͻ .01) which also coincided with increased trabecular separation (P Ͻ .001, Table 2 ). The latter results suggest a loss of the smaller trabecular rods, whereas the thicker rods remained. This assumption is in line with the SMI values that were significantly elevated in all OVX groups compared with the sham group (P Ͻ .001, Table 2 ). SMI was higher in the OVX-GW5 group compared with OVX-CTR (2.57 vs 2.27, P Ͻ .05, Table 2 ). Trabecular separation was increased in the OVX-GW1 and OVX-GW5 groups compared with OVX-CTR (1.84 and 2.02 vs 1.44 mm, P Ͻ .05, Table 2 ). The OVX-GW5 group Table 2 ).
Bone histomorphometry
Histomorphometric analyses of calcein parameters revealed that the low and high doses of GW501516 caused depression of osteoblastic function as reflected in significant reductions in interlabel width as a measure of osteoblastic matrix synthesis. Interlabel width was reduced in the OVX-GW1 and OVX-GW5 groups by 62% and 51%, respectively, compared with sham (P Ͻ .001) and by 37% and 21% compared with OVX-CTR (P Ͻ .01, Table 3 ). The changes in mineralizing surface reflecting tissue level bone turnover were equivocal with an unchanged surface extension in the high-dose GW group and a significant reduction in the low-dose group (P Ͻ .05, Table 3 ).
Relative mRNA expression and morphology in skeletal muscle
The GW501516 administration did not affect the relative gene expression of mitochondrial proteins (PDK4, CPT1, and UCP3) or PPAR␥ coactivator 1␣ (PGC-1␣) in the quadriceps muscle (Table 4 ). The morphologic analyses from the quadriceps muscle revealed no differences in myofiber area and number between the groups (Supplemental Data). Also, skeletal muscle fiber-type did not differ between the groups (data not shown).
Immunoassays
At the end of the study, there were no differences between the groups in plasma levels of osteocalcin, CTX, or insulin. OPG in plasma was below the detection limit in all groups, whereas RANKL was higher in the OVX-GW5 group relative to sham (79.3 vs 47.6 pg/mL, P Ͻ .01, Table  5 ). Adiponectin levels were lower in the OVX-GW5 compared with OVX-CTR (9.0 vs 20.1 g/mL, P Ͻ .001, Table 5 ). The OVX-GW1 and OVX-GW5 groups exhibited higher cholesterol levels than the sham group (P Ͻ .001, Table 5 ), whereas plasma triglycerides were higher in the OVX-GW5 group compared with all the other groups (P Ͻ .01, Table 5 ).
Differentiation and proliferation of osteoblasts and osteoclasts and release of OPG and RANKL from osteoblasts in vitro
Premature osteoblasts and osteoclasts from rat bone marrow were exposed to different doses of GW501516. We observed no effect of GW501516 on osteoblast differentiation, whereas the positive control pioglitazone reduced the number of mineralized colonies relative to GW (1nM and 100nM) and control (P Ͻ .05, Figure 3A) . OPG OVX-GW1 (n ‫؍‬ 10)
OVX-GW5 (n ‫؍‬ 10)
Osteocalcin, ng/mL 81.9 Ϯ 45.3 124.6 Ϯ 53.9 116.4 Ϯ 64.9 96.9 Ϯ 50.2 CTX, ng/mL 6.6 Ϯ 1. release to the cell medium after 7 days of osteoblast differentiation did not differ between GW and control conditions ( Figure 3C ), whereas secreted RANKL levels were below the assay detection limit for all conditions. GW501516 exposure did not affect the differentiation of rat bone marrow cells or RAW 264.7 cells into osteoclasts (Figure 3, D and E) . Also, the proliferation of MC3T3-E1 and RAW 264.7 cells was unaffected by GW501516 exposure (data not shown).
Relative expression of PPAR␦ target genes in rat L6 myoblasts in vitro
Relative to controls, the high dose of the PPAR␦ agonist GW501516 (0.1 M) resulted in a significant upregulation of UCP3, CPT1, LPL, and ANGPTL4 (P Ͻ .05, Figure 4) . The upregulation of CPT1 from GW501516 (0.1 M) was also higher relative to pioglitazone (10M). PDK4 and ANGPTL4 were significantly upregulated by the PPAR␦ agonist L165,041 (10M) relative to controls (P Ͻ .05, Figure 4 ).
Discussion
We have previously provided evidence that the PPAR␣ agonist fenofibrate has beneficial effects on bone both in intact and OVX rats, in contrast to the PPAR␥ agonist pioglitazone, which causes bone loss (9, 10) . In the present study, we show for the first time that activation of PPAR␦ by the agonist GW501516 caused impaired bone formation, leading to decreased BMD and deterioration of bone properties in OVX rats. In line with previous studies in rats, we also demonstrate that GW501515 increased the levels of triglycerides and cholesterol in plasma (20) .
GW501516 is recognized as a selective ligand for the ␦-subunit of PPARs and has been shown to have high affinity for PPAR␦ (29 -31) . GW501516 was administered at a low and high dose according to doses given in previous studies (18, 23) . Bone properties were assessed by DXA, CT, and histomorphometry. We observed that the gain in femoral BMD throughout the study was significantly lower in the OVX-GW5 group than in the OVX-CTR group. In accordance with this, both the OVX-GW groups displayed an increased trabecular separation at the proximal tibia compared with OVX-CTR. The OVX-GW5 group also had a lower cortical area fraction at this site, indicating that GW further exacerbates the negative skeletal effects of OVX. We also found that both low-and high-dose GW501516 consistently inhibited osteoblast activity as reflected by a reduction of the distance between calcein double labels. Remodeling activity, which is reflected in mineralizing surface (double labels only), differed, however, between the 2 OVX-GW groups, as the lowest value was seen in the low-dose group. We have no obvious explanation for this discrepancy, and further studies are needed to explore this. Still et al (14) demonstrated that activation of the PPAR␣/␦ subtypes by the natural ligand linoleic acid and the synthetic compound bezafibrate increased bone mass in male rats. They reported that both substances increased trabecular bone volume fraction, trabecular number, and cortical area as well as BMD at the tibial metaphysis compared with vehicle-treated animals. These effects were most pronounced in rats receiving linoleic acid. Because linoleic acid has shown greater affinity to the PPAR␦ isoform than the ␣-isoform, the authors suggested that these effects were mainly due to PPAR␦ activation (14) . However, studies from our group have shown that administration of fenofibrate, a PPAR␣-specific agonist, increased femoral BMD in intact female rats and prevented bone loss and deterioration of bone architecture and mechanical strength in OVX rats (9, 10) . Taken together, these results indicate that the osteogenic effects reported by Still et al (14) are mainly caused by activation of the PPAR␣ subtype, as our data demonstrate an inhibition of bone formation by activating the PPAR␦ subtype. Because Still et al (14) used male rats, it cannot, however, be ruled out that gender differences may explain the discrepancy in results.
Our data are in contrast to a recent study by Scholtysek et al (15) showing that pharmacological activation of PPAR␦ in OVX mice, applying the same agonist as in the present study, led to normalization of the RANKL to OPG ratio, a rebalancing of bone turnover, and the restoration of normal bone density. They also reported that activation of PPAR␦ amplified Wnt-dependent and ␤-catenin-dependent signaling and gene expression in osteoblasts, promoting osteoblast differentiation and bone nodule formation. We failed to show any effect of the specific PPAR␦ agonist GW501516 on differentiation of rat bone marrow cells to osteoblasts, and proliferation of MC3T3-E1 were also unaffected. In coculture studies, Scholtysek et al (15) observed increased expression of OPG and attenuation of osteoblast-mediated osteoclastogenesis, whereas no effect on osteoclast differentiation was seen when osteoclasts were generated in the absence of osteoblasts. The latter finding is in accordance with our data, because no effect of GW501516 exposure on osteoclast differentiation from rat marrow cells or RAW 264.7 cells was observed. The increase in RANKL levels in plasma in the high-dose GW group may imply stimulation of osteoclast differentiation and increased bone resorption. It should, however, be recalled that circulating RANKL may also derive from other sources (32) . The different effects of PPAR␦ agonism observed between these studies may be attributed to species differences, similar to what has previously been described for metabolic properties in skeletal muscle (19, 20) .
A possible mechanism, by which GW501516 may have affected bone metabolism in our study is through alterations in lipid profile and insulin sensitivity. Plasma cho- lesterol was elevated beyond sham level in both the OVX-GW groups. In postmenopausal women, a high level of serum cholesterol has been associated with low bone mass (33, 34) and has been suggested to accelerate bone loss (35) . It has also been demonstrated that cholesterol may negatively affect osteoblast function by interfering with estrogen receptors and liver X receptors (36) . The plasma level of triglycerides was higher in the highdose GW group compared with all the other groups. Triglycerides and fatty acids have been reported to inhibit osteoblast differentiation in vitro and to promote adipocytelike characteristics (37, 38) . Thus, the altered lipid profile may contribute to the reduced osteoblast activity observed in the GW groups by histomorphometry. Furthermore, we found low adiponectin levels in the high-dose GW group. Because adiponectin levels are inversely related to insulin resistance (39, 40) , reduced insulin sensitivity and glucose uptake may be one explanation for the increased lipid levels in our study. The latter assumption is in line with previous studies, as GW501516 administration to rats, at doses similar to those used in the present study, have been reported to induce elevated lipid levels in plasma and tissue (19, 20) . Also in these studies, the increased lipid levels were attributed to reduced insulin sensitivity and inhibited glucose uptake.
In the present study, GW501516 administration did not affect body weight, fat mass, or lean mass. Also, histological analyses of myofiber area in the quadriceps muscle did not reveal any differences between the OVX groups. Several studies on PPAR␦ activation have focused on skeletal muscle adaptations such as glucose handling, oxidative capacity, and lipid utilization (18, 29, 41) . Cresser et al (19) reported that GW501516 administration (4 mg/kg/d) to male rats worsened insulin-induced glucose transport in skeletal muscle and increased the expression of fatty-acid transport proteins (ie, fatty-acid translocase/ CD36) in skeletal muscle. This observation was supported by Ye et al (20) , who demonstrated that PPAR␦ activation by GW501516 (5 mg/kg/d) attenuated muscular insulin uptake in female rats, whereas the contrary was observed in mice, suggesting species-specific responses. In line with our findings, the effects observed in rats in the latter study coincided with increased levels of triglycerides in plasma and skeletal muscle. In the present study, no betweengroup differences in plasma insulin levels occurred. Yet, as mentioned earlier, the reduced plasma levels of adiponectin in the high-dose GW group could possibly reflect an inhibition of insulin-mediated glucose uptake in skeletal muscle. Together these findings indicate that PPAR␦ activation in rats promotes increased lipid mobilization, possibly as a result of attenuated insulin actions in skeletal muscle, which are not met by a corresponding increase in lipid metabolism.
In contrast to previous studies (20, 29) , we did not detect any effect of GW501516 on the mRNA expression of PPAR␦ target genes that are involved in mitochondrial fatty acid oxidation in skeletal muscle. GW501516 did, however, induce upregulation of PPAR␦ target genes in rat myoblasts, demonstrating that the compound given to the rats in vivo was an active PPAR␦ agonist. Previous rat studies that have observed in vivo effects of GW501516 on PPAR␦ target genes have administered this substance for 6 weeks or less (19, 20) . Therefore, the lack of in vivo effects in the present study could be due to the long-term exposure to GW501516, which may have blunted the PPAR␦ gene response. OVX has also been shown to reduce PPAR␦-mediated gene expression (21) . Thus, the absence of in vivo effects on mitochondrial proteins in our study could also be due to estrogen deficiency. Moreover, some studies have indicated that activation of adenosine monophosphate kinase is required for PPAR␦-mediated increases in lipid metabolism and mitochondrial biogenesis (18, 42) . Adenosine monophosphate kinase acts as an energy sensor in skeletal muscle cells and is activated during physical activity (18, 43) . This suggests that high activity levels may be required for PPAR␦-mediated increases in mitochondrial function, which could also explain the lack of mitochondrial effects in our study.
In summary, PPAR␦ activation by the agonist GW501516 in OVX rats caused impaired osteoblast function, attenuated femoral BMD, and caused deterioration of trabecular microarchitecture. GW501516 administration also induced elevated plasma levels of triglycerides and cholesterol without affecting skeletal muscle morphology or the relative gene expression of mitochondrial proteins.
